The rise of Viagra initially sparked a boom for pharma, nevertheless recent shifts present a murky outlook for those considering a stake. Lower-cost versions are reducing profits, and persistent litigation add further complexity to the situation. While certain companies might still benefit from adjacent products, the broader trend suggests a cau… Read More